Rucaparib is a groundbreaking medication in the treatment of certain cancers, primarily ovarian, fallopian tube, and peritoneal cancers. This drug, classified as a PARP inhibitor (Poly ADP-Ribose Polymerase inhibitor), has proven to be a significant advancement in the fight against cancer, particularly for patients with BRCA gene mutations. As a result, the demand for reliable and high-quality...
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Portuguese (Brazil)
Greek